Lewczuk Piotr, Beck Georg, Ganslandt Oliver, Esselmann Hermann, Deisenhammer Florian, Regeniter Axel, Petereit Hela-Felicitas, Tumani Hayrettin, Gerritzen Andreas, Oschmann Patrick, Schröder Johannes, Schönknecht Peter, Zimmermann Klaus, Hampel Harald, Bürger Katharina, Otto Markus, Haustein Sabine, Herzog Karin, Dannenberg Rainer, Wurster Ulrich, Bibl Mirko, Maler Juan Manuel, Reubach Udo, Kornhuber Johannes, Wiltfang Jens
Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.
Neurosci Lett. 2006 Nov 27;409(1):1-4. doi: 10.1016/j.neulet.2006.07.009. Epub 2006 Oct 11.
Currently, neurochemical dementia diagnostics (NDD) are increasingly entering routine clinical neurochemistry, offering improved early and differential diagnosis of dementias. However, there is an obvious lack of standardization in pre-analytical sample handling and systematic quality surveys. Therefore, in this study, 14 laboratories in Germany, Austria, and Switzerland were given aliquots of a human cerebrospinal fluid (CSF) sample, and were asked to measure Alzheimer's disease (AD) biomarkers (amyloid beta (Abeta) peptides, total Tau protein, and phosphorylated Tau protein (P-tau(181P))) according to their routine protocols.
The inter-laboratory coefficients of variation of the results obtained by the laboratories participating in this study were in the range of 20-30%. Although the results of this quality control survey are promising, the quality of measurements has to be further optimized.
目前，神经化学痴呆诊断（NDD）正越来越多地进入常规临床神经化学领域，为痴呆症提供了更好的早期诊断和鉴别诊断。然而，在分析前样本处理和系统质量调查方面明显缺乏标准化。因此，在本研究中，德国、奥地利和瑞士的14个实验室收到了一份人类脑脊液（CSF）样本的等分试样，并被要求根据其常规方案测量阿尔茨海默病（AD）生物标志物（淀粉样β（Aβ）肽、总 Tau 蛋白和磷酸化 Tau 蛋白（P-tau(181P)））。
参与本研究的实验室所获得结果的实验室间变异系数在20%至30%之间。尽管此次质量控制调查的结果很有前景，但测量质量仍需进一步优化。
